The new molecules of Kopran Ltd., KNC-1206, a bowel regulator and KNC-6, an anti-ulcerant which are now in the pre-clinical stage, are likely to reach phase I stage by 2007. After the phase I study, the company plans to out-license the molecules.
KNC-6 is a novel dual action anti-ulcerant having significant anti-secretory and cytoprotective properties with quick onset of action. The company had received approval from the US patent office for NCE of KNC-6 in 2003. Kopran has also filed patent application for KNC-6 in 30 other countries including Japan, Australia, Canada and the European countries.
"The delay is due to the peculiarity of molecules which need dog studies as part of pre-clinical studies. As it is not allowed in our country, we are scouting for companies to conduct the study outside," a senior company official told Pharmabiz. After finishing the phase I study successfully, we will out-license the molecule, he added.
Kopran developed the molecules and further studies were done in collaboration with other institutions. The research studies of the molecules were held at KEM Hospital, Mumbai, Bombay College of Pharmacy, KB Institute, Ahmedabad, Banaras Hindu University with the help of industry experts like Dr Ashok Vaidya and MD Nair.
Now, the synthesis works of new molecules for gastroenterology are on at the company's laboratory and it is expected that 5-6 new molecules will be launched soon.